Oesophageal squamous cell carcinoma (ESCC) is one of the most lethal cancers, owing to a high frequency of metastasis. However, little is known about the genomic landscape of metastatic ESCC. To identify the genetic alterations that underlie ESCC metastasis, whole-exome sequencing was performed for 41 primary tumours and 15 lymph nodes (LNs) with metastatic ESCCs. Eleven cases included matched primary tumours, synchronous LN metastases, and non-neoplastic mucosa. Approximately 50-76% of the mutations identified in primary tumours appeared in the synchronous LN metastases. Metastatic ESCCs harbour frequent mutations of TP53, KMT2D, ZNF750, and IRF5. Importantly, ZNF750 was recurrently mutated in metastatic ESCC. Combined analysis from current and previous genomic ESCC studies indicated more frequent ZNF750 mutation in diagnosed cases with LN metastasis than in those without metastasis (14% versus 3.4%, n = 629, P = 1.78 × 10 -5 ). The Cancer Genome Atlas data further showed that ZNF750 genetic alterations were associated with early disease relapse. Previous ESCC studies have demonstrated that ZNF750 knockdown strongly promotes proliferation, migration, and invasion. Collectively, these results suggest a role for ZNF750 as a metastasis suppressor. TP53 is highly mutated in ESCC, and missense mutations are associated with poor overall survival, independently of pathological stage, suggesting that these missense mutations have important functional impacts on tumour progression, and are thus likely to be gain-of-function (GOF) mutations. Additionally, mutations of epigenetic regulators, including KMT2D, TET2, and KAT2A, and chromosomal 6p22 and 11q23 deletions of histone variants, which are important for nucleosome assembly, were detected in 80% of LN metastases. Our study highlights the important role of critical genetic events including ZNF750 mutations, TP53 putative GOF mutations and nucleosome disorganization caused by genetic lesions seen with ESCC metastasis.
Introduction
Oesophageal cancer (EC) is one of the most aggressive cancers, and often presents with local invasion or regional lymph node (LN) metastasis at diagnosis [1] . The prognosis of patients with EC is poor, with 5-year survival rates of <20% [2] . With 400 000 deaths being attributed to EC worldwide, it is the sixth leading cause of cancer-related death [3] . The incidence of oesophageal squamous cell carcinoma (ESCC) shows remarkable worldwide geographical differences. In the Taihang Mountains of northern China, the incidence is 133 per 100 000 [4] , whereas Hong Kong is a moderate-risk region [5] , with an incidence of 10 per 100 000 in males according to the statistics from the Hong Kong Cancer Registry in 2014. In the endemic regions, ESCC is the most common histological type, accounting for 90% of all cases.
Metastasis is a complex multistep process involving local invasion of the extracellular matrix and stromal cell layers, invasion of blood vessels, survival in the circulation, arrival at distant organ sites, survival in foreign microenvironments, and growth proliferation at the metastatic sites [6] . It is the greatest contributor to ESCC deaths. Primary ESCC has been analysed by whole-exome sequencing (WES) or whole-genome sequencing in Chinese, Japanese and European populations. A number of driver genes in ESCC pathogenesis Genomic study for metastatic ESCC 501 have been identified [7] [8] [9] [10] [11] [12] . However, little is known about the molecular profiles of the metastatic ESCC and the genetic alterations contributing to metastasis.
In this study, we present the landscape of somatic alterations in Hong Kong ESCC patients, characterize the metastatic ESCCs in LNs by WES analysis, and directly compare the primary ESCCs and synchronous LN metastases. This study expands the registry of somatically disrupted driver genes, and reveals critical genetic events underlying ESCC metastasis.
Methods and materials

Study subjects
Tumour samples and histologically non-neoplastic mucosae at surgical resection margins were obtained from 45 ESCC patients from Queen Mary Hospital in Hong Kong. Institutional Review Board approval was obtained, and all study subjects signed consent forms. Supplementary material, Table S1 gives a description of the clinical characteristics of the cases. Fresh tumour samples from untreated patients were obtained at the time of surgery. Tumour cell contents from haematoxylin and eosin (H&E)-stained frozen sections were estimated by a pathologist (A.K.Y.L.). Representative images of H&E-stained frozen sections from the non-neoplastic mucosa, primary ESCCs and metastatic ESCCs in LNs are shown in supplementary material, Figure S1 . Over 80% of the samples contained at least 60% tumour (supplementary material, Table S2 ). A total of 56 tumours from 45 ESCC cases were sequenced, including 41 primary carcinomas and 15 LNs with metastatic carcinoma. For 11 of 45 ESCC cases, paired primary and synchronous LN metastases were available.
Whole-exome sequencing
Genomic DNAs were extracted from tumours and nonneoplastic mucosae at proximal surgical resection margins with the AllPrep DNA/RNA Mini kit (Qiagen, Hilden, Germany). Extracted DNA was analysed on 0.7% agarose gels; DNA quality and quantity were examined with a Nanodrop 1000 (Thermo Scientific, Waltham, MA, USA), Qubit (Life Technologies, Grand Island, NY, USA), and a bioanalyser (Agilent, Santa Clara, CA, USA). The library preparation, capture and sequencing were performed by the Centre for Genomic Sciences at the University of Hong Kong, as previously described [13] . In brief, 250 ng of genomic DNA was fragmented with an ultrasonicator (Covaris, Woburn, MA, USA), amplified with a NEBNext Ultra DNA library Prep Kit (NEB, Ipswich, MA, USA), hybridized to the Illumina TruSeq capture kit for enrichment, and then sequenced with the HiSeq 1500 sequencer (Illumina, San Diego, CA, USA) for 100-bp paired-end reads.
WES data analysis: detection of single-nucleotide variants (SNVs) and small indels Clean sequencing reads were aligned to the human genome (hg19) with BWA [14] . Picards were applied to sort reads and mark duplicates. Paired or triple samples from the same cases were merged. GATK [15] was then applied for local realignment around indels with base quality recalibration according to GATK Best Practices recommendations [16, 17] . After base quality recalibration, merged reads were split for individual samples. Germline variants were identified by GATK, and then examined for singletons and correct matching of samples from the same cases. SNVs were detected with Mutect [18] and Varscan2 [19] . Small indels were detected with Varscan2. In Mutect, we removed the SNVs with fewer than five reads supporting a mutant allele in tumour samples. In Varscan2, we considered only the high-confidence SNVs and indels with tumour variant allele frequency of >10%. SNVs with a minor allele frequency of >1% in 1000 genomes and ESP6500 databases were also removed from the analysis. Recurrent somatic mutations and low-quality mutations (mutant allele frequency of <10%) were manually checked in IGV alignment to remove false positives on the basis of mapping quality, base Phred quality score, and quality of adjacent regions. Loss-of-function (LOF) mutations were defined as stopgain, splicing and frameshift indels.
Detection of somatic copy number variations (SCNVs)
We used ADTEx [20] to detect the SCNVs. ADTEx is tailored for WES data, to infer SCNVs in ESCC genomes based on the normalized ratio of WES data from tumour and matched non-neoplastic mucosae. Copy number gain and loss were referred to as amplification and deletion, respectively.
RNA sequencing (RNASeq)
Four tumour pairs were subjected to RNASeq. Total RNAs were extracted with the AllPrep DNA/RNA Micro Kit (Qiagen). The ribosomal RNAs were depleted with the Ribo-Zero Magnetic Kit (Illumina). The Kapa Stranded RNA-seq Library Preparation kit was used for the library preparation, and the libraries were subjected to high-throughput sequencing by use of the HiSeq 1500 sequencer with 100-bp paired-end reads. 
Quantitative PCR (qPCR) copy number analysis
Copy numbers of CCND1 and HISTIH2BF were assessed in frozen tumours and matched non-tumour tissues. Copy number was determined by qPCR with the DNA-binding dye SYBR green and specific primer pairs (supplementary material, Table S3 ). METTL21A, selected from the WES data, served as a diploid control (supplementary material, Figure S2 ). Copy number changes were estimated with the delta-delta Ct method [7] .
Results
Identification of somatic mutations in primary and metastatic ESCCs
In this study, somatic changes of a total of 56 ESCC samples from 45 cases were characterized by WES (supplementary material, Table S1 ). We examined 41 primary tumours and 15 metastatic ESCCs in LNs. Eleven cases had matched primary tumours and synchronous LN metastases. The median average on-target coverage rates were 76-fold, 80-fold and 71-fold for the non-neoplastic mucosae, primary tumours, and LNs with metastatic ESCCs, respectively (supplementary material, Table S2 ). In 41 primary tumours, the median mutation rate was 3.6 mutations/Mb (range 1.5-11.2) in protein-coding regions and 2.7 non-silent mutations/Mb (range 0.9-7.1) (supplementary material, Table S4 ). This non-silent mutation rate is comparable to the recently reported mutation rates in ESCCs from Chinese patients (2.4-2.9 mutations/Mb) [7, 8, 10] . In 15 LNs with metastatic ESCCs, the median mutation rate was 3.6/Mb (range 1.1-7.6) in protein-coding regions and 2.6 non-silent mutations/Mb (range 0.7-5.4) (supplementary material, Table S5 ). There was no statistically significant difference in the overall mutation rate between primary and metastatic ESCCs ( Figure 1A ; supplementary material, Figure S3 ). Sanger sequencing on a subset of variants confirmed 96.4% (54 variants) somatic variants identified by WES (supplementary material, Table S6 ).
In primary ESCCs, TP53 (90.2%), KMT2D (24.4%), CDKN2A (12.2%) and ZNF750 (7.3%) were significantly mutated, with at least three non-silent mutations (MutSigCV P < 0.001) ( Figure 1B ; supplementary material, Table S7 ). In addition, multiple genes reported previously, including FAM135B (12.2%), NOTCH1 (9.8%), TET2 (9.8%), NFE2L2 (7.3%), RB1 (7.3%), FAT1 (7.3%), and NSD1 (7.3%), were mutated in at least 5% of the cases. We did not observe any significant association between the mutations of the putative driver genes TP53, KMT2D, CDKN2A and ZNF750 and smoking or drinking status (supplementary material, Table S8 ). In nodal metastases, four genes, i.e. TP53 (66.7%), KMT2D (40%), ZNF750 (13.3%), and IRF5 (13.3%), were mutated in at least two cases with MutSigCV P < 0.001 ( Figure 1B ; supplementary material, Table S9 ). There was no pronounced difference in the mutation frequency of these putative driver genes between the primary and metastatic ESCCs (FDR > 0.2; Figure 1C ). The gene mutation frequencies were also similar between the primary tumours with and without LN metastasis ( Figure 1D ).
We further examined the mutation profiles of 11 cases with primary tumours and synchronous LN metastases. The results showed that 50-76% of the protein-altering mutations in the metastatic ESCCs can be detected in the matched primary tumours (supplementary material, Figure S4 ). The mutations of the putative driver genes were generally found in both primary tumours and nodal metastases (supplementary material, Figure S5 ). We looked for the genes that were mutated in the nodal metastases but not in the primary tumours, and found that SYNE1 was recurrently mutated in metastatic ESCCs, whereas the reads supporting the mutations could be detected in the matched primary tumours at a much lower allele frequency, and were thus rejected by Mutect and Varscan2 (supplementary material, Figure S6 ). This result shows that the tumour cells in the nodal metastases with SYNE1 mutations are likely to originate from a subclone of the primary tumours, with subsequent clonal expansion in the LNs.
Mutational signatures in primary and metastatic ESCCs
Two predominant signatures were identified in the primary tumours, as reported previously [7, 9] . Signature A is characterized as substitutions in CpG dinucleotides due to an increased rate of spontaneous 5-methylcytosine deamination. Signature B is characterized as substitutions involving C to G/T in TpCpX trinucleotides (Figure 2A, B) , and was associated with the APOBEC-mediated mutations [21] . No smoking-associated signature characterized by C > A mutations was identified. Interestingly, the APOBEC-mediated signature was much weaker in the metastatic ESCCs than in the primary tumours (P = 0.024; Figure 2C , D; supplementary material, Figures S7 and S8). We did not detect discrepancies in tumour contents or coverage between primary and metastatic ESCCs (supplementary material, Figure S9 ). No bias in sample selection and sequencing depth was observed.
TP53 mutations in primary and metastatic ESCCs
TP53 was the most significantly mutated gene in the primary (90.5%) and metastatic (66.7%) ESCCs. The recurrent missense mutations p.R175H, p.Y220C, p.R248Q/W and p.R273C/H occurred in at least 5% of the primary tumours ( Figure 3A) . The hot spots for TP53 missense mutation in the Hong Kong cohort were slightly shifted as compared with the ESCC cases from high-risk regions (Taihang Mountains and Chaoshan District in China), but were similar to those of combined ESCC cases from high-risk and low-risk regions (supplementary material, Figure S10 ), suggesting that Hong Kong ESCC cases constitute a mixed cohort from different risk regions. Interestingly, the patients with TP53 missense mutations had much shorter survival times than those with LOF mutations or without mutation ( Figure 3B ). The association between TP53 missense mutations and overall survival was independent of clinical parameters, including stage and age [adjusted hazard ratio (HR) = 3.36, 95% confidence interval (CI) 1.51-7.49, P = 0.003] (supplementary material, Table S10 ). A similar frequency (∼70%) of nodal metastasis at diagnosis was observed in the patients with TP53 missense mutations and those with LOF mutations, suggesting that the overall TP53 missense mutations had no significant association with the LN metastasis. In the metastatic ESCCs, missense mutations (p.R273H, p.R273C, p.V272 M, p.I255F, p.V157A, and p.F109C), truncating mutations (p.R209* and p.S183*) and frameshift indels (p.T230 fs and p.L93 fs) were identified ( Figure 3A ).
ZNF750 mutations in primary and metastatic ESCCs
ZNF750 is a putative tumour suppressor in ESCC [7, 9] . In this study, it was mutated in both primary (7.3%) and metastatic (13%) ESCCs (MutSigCV P < 0.001). We further examined 49 ZNF750 mutations, including 32 LOF and 17 missense mutations, identified from a total of 629 primary tumours in this current study and previous genomic studies from both northern and southern China, and Japan [7] [8] [9] [10] [11] . The patients with ZNF750 mutations accounted for 9.4% of the total cases ( Figure 4A ), and were observed among both northern and southern Chinese with similar mutation frequencies (∼6%) (supplementary material, Figure S11 ). This result confirmed that the patients carrying these mutations more often had LN metastasis at diagnosis than those without LN metastasis (14% versus 3.4%, P = 1.78 × 10 -5 ; Figure 4B ). In our samples, the ZNF750 LOF mutations, including p.Y302* and p.F213 fs, were found in two synchronous LN metastases and matched primary tumours. ZNF750 deletion was also observed in two cases carrying ZNF750 LOF mutations ( Figure 4C ), suggesting biallelic gene inactivation via mutation and deletion. To further investigate the clinical impact of ZNF750 genetic alterations, we analysed the ZNF750 mutation data for 184 cases with EC in the study of the The Cancer Genome Atlas [12] . The survival analysis showed that the cases with genetic alterations including point mutations and copy number variations at ZNF750 had much shorter disease relapse-free survival (log-rank test P = 0.0006; supplementary material, Figure S12) .
At the mRNA level, downregulation of ZNF750 was found in >80% of the cases (supplementary material, Figure S13 ). Gene set enrichment analysis (GSEA) using the publicly available microarray data (GSE23400, n = 53) indicated that ZNF750 expression was correlated with the gene sets that are the targets of the polycomb repressive complex (PRC) 1 protein BMI1 and PRC2 protein SUZ2 (FDR < 0.15; supplementary material, Figure 4D ). Expression levels of BMI1 and SUZ12 were significantly elevated in ESCCs (supplementary material, Figure S14 ).
Point mutations in epigenetic regulators in primary and metastatic ESCCs
Aberrant epigenetic changes were often observed in cancers. In our study, KMT2D, encoding a histone methyltransferase, was mutated in 24.4% of the primary tumours, and was considered to be one of the putative driver genes in ESCC pathogenesis. We identified a total of 13 mutations, and 10 of 13 (76.9%) were LOF mutations. In addition, mutations of TET2, encoding a genes. The cases with mutations in these genes often had LN metastasis (53.6% versus 15.4%, P = 0.039), suggesting a potential role of the mutations in these epigenetic regulators in ESCC metastasis.
Nucleosome core deletion in primary and metastatic ESCCs
In primary ESCCs, deletion frequently occurred on chromosomes 3p21 and 9p21 (CDKN2A/CDKN2B) and amplification was often identified at chromosomes 3q12-13, 3q21-29 (PIK3CA/TERC/SOX2/TP63), 5p14-15 (TERT), 8q21-24 (MYC), and 11q13 (CCND1/FGFs/SHANK2) (supplementary material, Figure S15 ). The qPCR copy number analysis confirmed the selected SCNVs in 83.3% of the samples (supplementary material, Table S11 ).
Deletion at chromosome 6p22.1-22.2 was identified in 53.3% of the LN metastases and in only 39% of the primary ESCCs ( Figure 1C ). The cases with chromosome 6p22 deletion more often had LN metastasis at diagnosis than those without any deletion detected (P = 0.045) ( Figure 5A ). Among 11 cases with matched samples, chromosome 6p22 deletion was recurrently found in three synchronous nodal metastases, but these changes were not detectable in the primary tumours ( Figure 5B ). We further investigated the genes deleted in the metastatic ESCCs. Of 204 genes deleted in at least seven of 15 (46.7%) cases (supplementary material, Table 12 ), genes involved in nucleosomal assembly were significantly enriched (adjusted P = 3.1 × 10 -15 ), but this enrichment was not observed in 91 genes deleted in at least 19 of 41 (46.3%) primary tumours (supplementary material, Table 13 ). These nucleosomal histones include genes from histone cluster 1 on chromosome 6p22 ( Figure 5C ) and the H2A histone variant (H2AFX) on chromosome 11q23.3. Survival analysis revealed that the cases harbouring the chromosome 6p22 deletion or chromosome 11q23 deletion at H2AFX had much shorter overall survival than those without deletion in these two regions ( Figure 5D ; supplementary material, Table S9 ).
Copy number gain in telomerase subunit genes in primary and metastatic ESCCs
Telomerase is an enzyme complex that adds telomeric repeats to ends of chromosomes. The core components of telomerase include telomerase reverse transcriptase (TERT) and the telomerase RNA component (TERC) [22] . TERT maps to chromosome 5p15.33, and amplification of the TERT region has been reported in ESCCs [12] . TERC maps to chromosome 3q26. Amplification at TERT and TERC was observed in 65.9% and 58.5% of the primary ESCCs, respectively. A trend of reduced TERT amplification frequency in LN metastases accounted for 20% of the cases (P = 0.028, FDR = 0.31). TERC amplification was still frequently observed, accounting for 66.7% of nodal metastases (supplementary material, Table S13 ).
Discussion
Using WES analysis, we investigated the genomic changes in ESCC metastasis cases in primary tumours and LNs and associations with clinical outcomes. Mutations of the putative driver genes were generally found in both primary tumours and LN metastases, and the variant allele frequencies correlated in >70% of the paired specimens. Nodal metastases appear to be seeded from multiple clones from the primary tumours. Critical tumourigenic events observed in the primary tumours are detected in the synchronous LNs. We believe that selectively conserved tumourigenic events, which drive metastasis in ESCCs, also play an important role in making the primary tumours biologically and intrinsically aggressive, leading to the high frequency of local invasion and LN metastasis observed at diagnosis. The APOBEC-mediated signature observed in primary ESCCs was much weaker in the metastatic cancers. It has been reported that the APOBEC-attributable 508 W Dai et al mutations may be both early and late events during tumour evolution, depending on cancer type [23] . Our data show that APOBEC members play a minor role in ESCC metastasis. Tobacco and alcohol consumption are important environmental risk factors for ESCC. The association between smoking and ESCC has been well established in Western and Japanese populations [12, 24] . We did not identify a smoking-associated signature in either primary or metastatic ESCCs, and there was no significant association of genetic alterations of the putative driver genes with smoking or drinking status. Although this result is consistent with the findings from the previous genomic studies on ESCC in the Chinese population [7, 10] , <15% of the cases in this study were non-smokers and non-drinkers, which may limit the power of the association analysis.
TP53 is frequently mutated in both primary and metastatic ESCCs. Previously, we reported that TP53 mutations appeared to have a role in predicting the clinical outcome of patients with ESCC, but results did not show statistical significance [25] . In the current study, we further categorized TP53 mutations as missense or LOF mutations, and demonstrated a significant association between TP53 missense mutations and shorter overall ESCC patient survival. This association indicates the important functional impact of these missense mutations in ESCC disease progression. The incidence of the LN metastasis at diagnosis, however, showed no significant difference between the patients with missense mutations and those with LOF mutations, suggesting that not all TP53 missense mutations identified in this study contribute to ESCC metastasis. Nevertheless, two missense mutations were found in the metastatic ESCCs at codon p.R273 (p.R273C and p.R273H). Previous studies showed that p.R273H and p.R273C mutants enhanced cell proliferation, invasion and drug resistance in vitro [26] ; p.R273H knock-in increased the incidence of highly metastatic carcinomas in vivo [27] . Our data and previous studies imply that these two mutations are likely to be gain-of-function (GOF) mutations, and contribute to invasion and metastasis.
ZNF750 was recurrently mutated in LN metastases. An important association between ZNF750 mutations and LN metastasis was observed when the results on ESCC from current and previous genomic studies were combined. Moreover, the genetic alterations at ZNF750 were associated with early disease relapse. ZNF750 plays an essential regulatory role in controlling epithelial homeostasis by inhibiting progenitor genes, while inducing differentiation [28] [29] [30] . In squamous cell carcinomas, ZNF750 genetic lesions, including point mutations and deletions, were exclusively observed; they drive differentiation and regulate cell growth, migration, and invasion [7, 31] . In ESCCs, ZNF750 expression was associated with suppression of the PRC1 protein BMI1 and the PRC2 protein SUZ12. BMI1 maintains the self-renewal and proliferative capacity of the cells, and promotes metastasis and chemoresistance [32, 33] . Thus, suppression of PCR1 and PRC2 is one of the possible mechanisms inhibiting metastasis caused by ZNF750. Taking the data together, we believe that ZNF750 is a metastasis suppressor in ESCCs; loss of wild-type ZNF750 resulting from genetic lesions can abrogate its inhibition of migration and invasion, promote the persistence of cancer-initiating cells, and increase stemness and proliferative capacity.
The epigenetic regulators KMT2D, KAT2A and TET2 were mutated in 60% of the metastatic ESCCs and in only 15.3% of the primary ESCCs without LN metastasis, suggesting an important role of these epigenetic regulators in ESCC metastasis. Knockdown of TET2 increases the invasive activity of ESCCs, and a higher frequency of KMT2D mutations is found in the metastatic tumours than in the primary tumours [11, 34] . The link between the epigenetic regulators and epithelial-mesenchymal plasticity has been demonstrated in cancers [35] . Moreover, 66.7% of the metastatic ESCCs in LNs had deletion of chromosome 6p22 or 11q23, and the cases with these deletions often had LN metastasis. Histone cluster 1 plays an important function in nucleosome assembly and telomere organization. The variant histone gene H2AFX on chromosome 11q23 plays essential roles in DNA double-strand break repair and genomic stability; it is a regulator of epithelial-mesenchymal transition (EMT) [36, 37] . In total, 80% of the metastatic ESCCs had point mutations of epigenetic regulators or deletion of histone variants, and >50% of the cases had both genetic events. These results show that these genetic lesions may function collectively, leading to chromatin disorganization, abnormal DNA packaging and repair, and deregulation of the EMT programme, which promote ESCC metastasis. In addition, a trend of decreased frequency of TERT amplification at chromosome 5p15.33 was detected in metastatic ESCCs, accounting for 20% of the cases. Telomeres are composed of the repetitive (TTAGGG) n repeats bound by shelterins, which protect them from being recognized as DNA double-strand breaks. The maintenance of telomere length is crucial for tumour cell survival. Our data suggest that TERT amplification is negatively selected in metastatic ESCCs.
Chemoresistance is one of the major causes of treatment failure in patients with ESCC. A few genetic alterations identified in this study are known to be related to the sensitivity of chemotherapy. For example, some TP53 GOF mutations, such as p.R248Q/W, are associated with chemoresistance [38, 39] . Another example is ATR, which is mutated in 4.8% of the primary ESCCs and in 6.7% of the metastatic ESCCs. It has been reported that ATR mediates cisplatin resistance in a TP53 genotype-dependent manner, and ATR mutation can sensitize the cancer cells to cisplatin treatment [40] . Thus, characterization of ESCCs by WES would be helpful to identify the actionable targets to guide clinicians in optimizing the treatment strategy to improve the clinical outcome of ESCCs. Figure S1 . Representative images of H&E-stained fresh frozen tissue sections Table S8 . Association analysis between mutations of putative driver genes and smoking and drinking 
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